{"filing":{"accession_number":"0001140361-26-028604","cik":"0002081043","ticker":"ATAI","company_name":"AtaiBeckley Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"ef20078103_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126028604/ef20078103_8k.htm"},"events":[{"id":18276,"run_id":16426,"accession_number":"0001140361-26-028604","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"AtaiBeckley Inc. entered into a definitive Agreement and Plan of Merger with Eli Lilly and Company on July 15, 2026, whereby Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash plus contingent value rights worth up to $2.50 per share, representing approximately $2.8 billion in upfront equity value plus $1.0 billion in potential milestone payments.","company_name":"AtaiBeckley Inc.","ticker":"ATAI","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17038,"accession_number":"0001140361-26-028604","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"AtaiBeckley entered into a definitive Agreement and Plan of Merger with Eli Lilly and Company on July 15, 2026, whereby Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash plus contingent value rights worth up to $2.50 per share. The transaction represents an aggregate equity value of approximately $2.8 billion upfront plus $1.0 billion in potential CVR payments, constituting a material acquisition and change of control of the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:28:40.947059+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17039,"accession_number":"0001140361-26-028604","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses execution of a definitive Merger Agreement whereby Eli Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in contingent value rights, representing approximately $2.8 billion in upfront equity value plus $1.0 billion in potential milestone payments. This is a material acquisition transaction requiring stockholder approval and expected to close in Q3 2026, clearly falling within the ma_activity category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:28:40.947059+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17038,"accession_number":"0001140361-26-028604","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"AtaiBeckley entered into a definitive Agreement and Plan of Merger with Eli Lilly and Company on July 15, 2026, whereby Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash plus contingent value rights worth up to $2.50 per share. The transaction represents an aggregate equity value of approximately $2.8 billion upfront plus $1.0 billion in potential CVR payments, constituting a material acquisition and change of control of the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:28:40.947059+00:00","company_name":"AtaiBeckley Inc.","ticker":"ATAI","filing_date":"2026-07-16"},{"id":17039,"accession_number":"0001140361-26-028604","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses execution of a definitive Merger Agreement whereby Eli Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in contingent value rights, representing approximately $2.8 billion in upfront equity value plus $1.0 billion in potential milestone payments. This is a material acquisition transaction requiring stockholder approval and expected to close in Q3 2026, clearly falling within the ma_activity category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:28:40.947059+00:00","company_name":"AtaiBeckley Inc.","ticker":"ATAI","filing_date":"2026-07-16"}]}